| pubmed-article:17621873 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17621873 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:17621873 | lifeskim:mentions | umls-concept:C1514526 | lld:lifeskim |
| pubmed-article:17621873 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17621873 | pubmed:dateCreated | 2007-7-11 | lld:pubmed |
| pubmed-article:17621873 | pubmed:abstractText | A greater understanding of the biology of myeloma has focused research on the identification of novel target-based treatment strategies. Proteasome inhibition represents one such approach and the introduction of bortezomib, the first-in-class proteasome inhibitor, has been a major breakthrough in the treatment of multiple myeloma. As a result of its novel mechanism of action, bortezomib has been shown to induce responses in patients previously refractory to treatment, and results in increased progression-free and overall survival rates. The current understanding of the biology of the proteasome and the mechanism by which proteasome inhibition leads to myeloma cell death is described in this review. The role of proteasome inhibitors in the management of myeloma is also discussed. | lld:pubmed |
| pubmed-article:17621873 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17621873 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17621873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17621873 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17621873 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:17621873 | pubmed:issn | 1472-4472 | lld:pubmed |
| pubmed-article:17621873 | pubmed:author | pubmed-author:DaviesFaith... | lld:pubmed |
| pubmed-article:17621873 | pubmed:author | pubmed-author:MorganGareth... | lld:pubmed |
| pubmed-article:17621873 | pubmed:author | pubmed-author:Kanagasabaphy... | lld:pubmed |
| pubmed-article:17621873 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17621873 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:17621873 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17621873 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17621873 | pubmed:pagination | 447-51 | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:meshHeading | pubmed-meshheading:17621873... | lld:pubmed |
| pubmed-article:17621873 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17621873 | pubmed:articleTitle | Proteasome inhibition and multiple myeloma. | lld:pubmed |
| pubmed-article:17621873 | pubmed:affiliation | Royal Marsden Hospital, Haemato-Oncology Unit, Downs Road, Sutton, Surrey SM2 5PT, UK. | lld:pubmed |
| pubmed-article:17621873 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17621873 | pubmed:publicationType | Review | lld:pubmed |
